Our latest news

Cachexia is a metabolic disorder that causes uncontrolled weight loss and muscle wasting in chronic diseases and cancer. A new study by Helmholtz Munich, in collaboration with the Institute of Physiology of the Czech Academy of Sciences in Prague, Heidelberg University Hospital, the German Center for Diabetes Research (DZD), and the German Center for Cardiovascular […]

Inflammation has to work fast against pathogens—but it can’t get out of control. Researchers at the German Cancer Research Center (DKFZ) have now deciphered in more detail how the organism masters this balancing act. Their work shows that cells use two different strategies to precisely control inflammatory genes and thus precisely regulate the inflammatory response. […]

Daniel Kirschenbaum from the German Cancer Research Center (DKFZ) is developing new methods to find out exactly how immune cells are suppressed by malignant brain tumors. He is being supported in this by the EACR-Mark Foundation and the Pezcoller Foundation with the Rising Star Award, which is endowed with 100,000 euros. Tumor cells have a […]

In 2025, the bioRN cluster experienced a strong and dynamic expansion as many new members joined its growing network. This influx of new companies and institutions further strengthened the cluster’s expertise, diversity, and innovative power. The cluster is now pleased to introduce these new members and highlight the diverse capabilities they bring, further reinforcing its […]

HEIDELBERG, Germany – January 9, 2026 – ariadne.ai (Germany) GmbH today announced it has been awarded €518,000 in non-dilutive funding from the State of Baden- Württemberg (Invest BW) for its ambitious new project, TumorTwin. The project aims to revolutionize the treatment of Glioblastoma, one of the deadliest and most aggressive brain tumors, by creating a […]

Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.   The acquisition adds to Amgen’s […]

Science Minister Olschowski: A medical flagship model that will raise teaching, research and care to a new level of quality A medical flagship model that will raise teaching, research and care to a new level of quality and will be widely noted internationally: With these words, Petra Olschowski, Baden-Württemberg’s science minister, expressed appreciation of the […]

Bayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance diagnosis for cardiac amyloidosis / PET tracer AT-01 in Phase III and SPECT tracer AT-05 in Phase I of clinical development specifically designed for the diagnosis of cardiac as well as other types of systemic amyloidosis […]

Heidelberg, Germany, January 13, 2026 – BioMed X announced today the launch of a pilot initiative with Harvard University under BioMed X’s XBridge framework to support structured research collaborations between academic investigators and pharmaceutical industry scientists through sponsored research agreements. The XBridge pilot is designed to connect senior biomedical researchers and principal investigators at Harvard with researchers from pharmaceutical companies seeking to […]